Acorda Therapeutics (NASDAQ:ACOR) and Its Competitors Financial Analysis

Acorda Therapeutics (NASDAQ: ACOR) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Acorda Therapeutics to related businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Institutional and Insider Ownership

50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.9% of Acorda Therapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Acorda Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acorda Therapeutics 2 10 2 0 2.00
Acorda Therapeutics Competitors 843 3192 11577 230 2.71

Acorda Therapeutics presently has a consensus target price of $20.77, indicating a potential upside of 1.56%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.60%. Given Acorda Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Acorda Therapeutics has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Acorda Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Acorda Therapeutics $519.60 million -$34.61 million -16.90
Acorda Therapeutics Competitors $284.30 million $34.29 million 131.13

Acorda Therapeutics has higher revenue, but lower earnings than its rivals. Acorda Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Acorda Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Acorda Therapeutics’ rivals have a beta of 1.79, indicating that their average stock price is 79% more volatile than the S&P 500.


This table compares Acorda Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics -10.25% -8.18% -4.15%
Acorda Therapeutics Competitors -5,355.72% -433.57% -39.04%


Acorda Therapeutics rivals beat Acorda Therapeutics on 8 of the 12 factors compared.

About Acorda Therapeutics

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply